AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8142644
Drug: Hu‐M195 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hu‐M195 at 0.5, 1.0, 3.0, and 10.0 mg/m2
Trial: 8142644
Drug: Hu‐M195 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hu‐M195 at 3 mg/m2
Trial: 3344597
Drug: Butorphanol 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 4 mg (i.m.)
Trial: 3344597
Drug: Butorphanol 2
RxNorm normalized name: butorphanol 2 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 2 mg (i.m.)
Trial: 3344597
Drug: Meperidine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 80 mg (i.m.)
Trial: 3344597
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (Butorphanol 4 mg, Butorphanol 2 mg, Meperidine 80 mg)
Trial: 9756188
Drug: Continued theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued theophylline treatment (400 mg/day) for 6 weeks
Trial: 3407871
Drug: Suxamethonium 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 50 mg
Trial: 3407871
Drug: Suxamethonium 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 15 mg
Trial: 3407871
Drug: Suxamethonium 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 25 mg
Trial: 3407871
Drug: Suxamethonium 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 15 mg, 25 mg, 50 mg
Trial: 28341107
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of morphine 0.1 mg kg–1 with levobupivacaine 0.5% (1 mg kg–1; group LevoBM)
Trial: 28341107
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of morphine 0.1 mg kg–1 with bupivacaine 0.5% (1 mg kg–1; group BM)
Trial: 25952661
Drug: BAY 81-8973
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 81-8973 (50 IU kg(-1) dose)
Trial: 25952661
Drug: BAY 81-8973
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 81-8973 (single and multiple dosing)
Trial: 15282655
Drug: Bivalirudin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin with provisional use of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor
Trial: 15282655
Drug: Low-dose unfractionated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose unfractionated heparin (UFH) plus planned GP IIb/IIIa inhibitor
Trial: 15282655
Drug: Bivalirudin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin with provisional use of GP IIb/IIIa inhibitor
Trial: 1490794
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation (S)
Trial: 26392328
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (DE) 150 mg with omeprazole
Trial: 26392328
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (DE) 150 mg with rabeprazole
Trial: 21948118
Drug: Smartseal sealer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartseal sealer and a 0.06 taper Smartpoint calibrated to apical tip size 30
Trial: 17469884
Drug: Paroxetine (AD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (AD therapy)
Trial: 15669706
Drug: Three narrow‐diameter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three narrow‐diameter roughened‐surface implants placed in edentulous maxillas using a one‐stage surgical procedure.
Trial: 10610011
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 500 mg/day fasting
Trial: 10610011
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 500 mg/day with food
Trial: 10610011
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 750 mg/day fasting
Trial: 10610011
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 750 mg/day with food
Trial: 10610011
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 1000 mg/day fasting
Trial: 10610011
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 1000 mg/day with food
Trial: 10610011
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 1500 mg/day with food
Trial: 10610011
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 750 mg twice/day with food
Trial: 10610011
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension with TMP-SMX
Trial: 10610011
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension with food
Trial: 10610011
Drug: Atovaquone suspension
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone suspension 1500 mg/day
Trial: 1725026
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of ramipril daily
Trial: 1725026
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of ramipril in combination with 20 mg of furosemide daily
Trial: 6390537
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of multiple chemotherapy and radiotherapy for patients with positive laparotomy or unfavorable prognostic indicators
Trial: 31215538
Drug: Standard conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conservative treatment (control group, n=50)
Trial: 29898066
Drug: EndoVac (EV)
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EndoVac (EV) + 2% Chlorhexidine gel + saline solution (CHXg + SS)
Trial: 29898066
Drug: EndoVac (EV)
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EndoVac (EV) + 2% Chlorhexidine solution (CHXs)
Trial: 29898066
Drug: EndoVac (EV)
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EndoVac (EV) + Saline solution (SS)
Trial: 29898066
Drug: Conventional irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional irrigation (CI) + 2% Chlorhexidine gel + saline solution (CHXg + SS)
Trial: 29898066
Drug: Conventional irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional irrigation (CI) + 2% Chlorhexidine solution (CHXs)
Trial: 29898066
Drug: Conventional irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional irrigation (CI) + Saline solution (SS)
Trial: 24290979
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment for opioid dependence
Trial: 24290979
Drug: Neonates requiring
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonates requiring pharmacotherapy for NAS
Trial: 24290979
Drug: Neonates not
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonates not requiring pharmacotherapy for NAS
Trial: 18084949
Drug: Epidermal growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal growth factor receptor monoclonal antibodies (EGFR‐MoABs)
Trial: 18084949
Drug: Anti‐angiogenic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐angiogenic drugs
Trial: 10634923
Drug: Nutritional counseling
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional counseling with fortified drink supplements (group B)
Trial: 7972617
Drug: Naloxone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (5 mg i.v.)
Trial: 45539
Drug: Penbutolol 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol 25 mg
Trial: 31448846
Drug: Lofexidine (LFX)
DrugBank: Lofexidine (DB04948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lofexidine (LFX) 2.4 mg/day
Trial: 23949882
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/week, with dose escalation until serum total testosterone of 20 nmol/l)
Trial: 12800099
Drug: rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (4 mg/d) for 12 weeks
Trial: 8781766
Drug: Troglitazone (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (200, 400, 600, or 800 mg once daily, or 200 or 400 mg twice daily)
Trial: 8781766
Drug: Troglitazone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (600 and 800 mg/day)
Trial: 8781766
Drug: Troglitazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (400 and 600 mg doses)
Trial: 8781766
Drug: Troglitazone (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (highest doses)
Trial: 3884746
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of cyclophosphamide (CTX), Adriamycin (ADR), and DDP (CAD)
Trial: 29231524
Drug: Need-in-row therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Need-in-row therapy
Trial: 24863090
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise training program (60 minutes of aerobic and stretching exercises, twice a week for 12 weeks)
Trial: 18407904
Drug: Protein powder
RxNorm normalized name: Pre-Protein Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein powder supplement aiming at 36 g of protein per day
Trial: 18407904
Drug: Energy and
RxNorm normalized name: Energy And Endurance Testosterone UP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy and protein supplements aiming at 37.6 g of protein and 500 kcal per day
Trial: 10071426
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: 240 mg CBS every 12 h for 6 weeks
Trial: 10071426
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: 240 mg CBS every 12 h for 6 weeks, plus metronidazole 500 mg every 8 h plus tetracycline 500 mg every 8 h for 10 days
Trial: 10071426
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: 240 mg CBS every 12 h for 6 weeks, plus metronidazole 500 mg every 8 h plus amoxicillin 750 mg every 12 h for 10 days
Trial: 28111410
Drug: Tolvaptan treatment
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan treatment for 15 days or longer (15DL)
Trial: 28111410
Drug: Tolvaptan treatment
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan treatment for 14 days or shorter (14DS)
Trial: 24197826
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (NS) 5 ml injected into the epidural space before catheter insertion
Trial: 22067058
Drug: Immediate 2-weeks
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immediate 2-weeks treatment group (N=28)
Trial: 17923489
Drug: GSK364735 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK364735 (50 to 400 mg single doses, 100 to 600 mg repeated doses for 8 days)
Trial: 8179044
Drug: Audio self‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audio self‐administered questionnaire
Trial: 8179044
Drug: Written self‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written self‐administered questionnaire
Trial: 23544125
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/d plus Ezetimibe 10 mg/d
Trial: 14615636
Drug: Corticosteroids (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (standard treatment)
Trial: 14615636
Drug: Adjunctive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive agents (new treatments)
Trial: 10636509
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) therapy
Trial: 26811529
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Oxaliplatin and FU + LV)
Trial: 15321815
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Fe and 10 mg Zn (Fe+Zn group)
Trial: 9843082
Drug: Ultrahigh-dose methylcobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrahigh-dose methylcobalamin (25 mg/day, intramuscularly, for 14 days)
Trial: 9843082
Drug: Low-dose methylcobalamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methylcobalamin (0.5 mg/day, intramuscularly, for 14 days)
Trial: 22515
Drug: Pipothiazine palmitate
RxNorm normalized name: Pipothiazine palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipothiazine palmitate (100 mg, injected every 4th week)
Trial: 22515
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate (25 or 37.5 mg, injected every 3rd week)
Trial: 31136834
Drug: Guideline-based care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based care (GBC) + referral to Psychologically Informed Physical Therapy (PIPT)
Trial: 23497371
Drug: Extended anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended anticoagulation treatment (continuing warfarin treatment for a further 2 years)
Trial: 23497371
Drug: Routine anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine anticoagulation treatment (discontinuing warfarin treatment after 3-6 months)
Trial: 15717477
Drug: Oral polio
RxNorm normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral polio vaccine (OPV) first dose
Trial: 15717477
Drug: Oral polio
RxNorm normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral polio vaccine (OPV) second dose
Trial: 11911558
Drug: Tramadol/acetaminophen (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/acetaminophen (37.5 mg/325 mg) tablets QID for 10 days
Trial: 10414461
Drug: Neuronal autoantibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuronal autoantibody titers during chemotherapy
Trial: 7672496
Drug: GLP-1 [7-36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 [7-36 amide] (all doses) after glucose stimulation
Trial: 7672496
Drug: GLP-1 [7-36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 [7-36 amide] (all doses)
Trial: 1983712
Drug: Niperotidine (460
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niperotidine (460 mg administered at 22.00)
Trial: 23924233
Drug: Fluticasone Furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone Furoate (FF) 100 μg
Trial: 23924233
Drug: Fluticasone Furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone Furoate and Vilanterol (FF/VI) 100/25 μg
Trial: 18257343
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Chinese patent medicine
Trial: 15312215
Drug: N-acetyl-L-cystein (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-cystein (NAC) infusion (150 mg/kg bolus followed by 12.5 mg/kg/hour for 6 hours)
Trial: 15312215
Drug: Dextrose (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose (5% solution) administered at the same dosage as NAC
Trial: 9542480
Drug: Avitriptan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avitriptan (150 mg doses, 2 hours apart)
Trial: 7992348
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg mebendazole (Janssen)
Trial: 7992348
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg mebendazole (Pharmamed)
Trial: 2730505
Drug: guided mastery
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guided mastery treatment based on self‐efficacy theory
Trial: 2730505
Drug: stimulus exposure
RxNorm normalized name: Limulus polyphemus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stimulus exposure treatment
Trial: 2730505
Drug: delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delayed treatment
Trial: 26246322
Drug: Total Protein
RxNorm normalized name: Total Protein Reagent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Protein Intake (TPro) ≥1.0 to <1.2 g · kg(‐1) · d(‐1)
Trial: 26246322
Drug: Total Protein
RxNorm normalized name: Total Protein Reagent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Protein Intake (TPro) ≥1.2 g · kg(‐1) · d(‐1)
Trial: 26246322
Drug: Total Protein
RxNorm normalized name: Total Protein Reagent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Protein Intake (TPro) <1.0 g · kg(‐1) · d(‐1)
Trial: 20390281
Drug: Mud‐bath therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud‐bath therapy with mineral water from the Sillene Spring at Chianciano Spa
Trial: 11765592
Drug: Cetirizine hydrochloride
RxNorm normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg (CTZ/PSE)
Trial: 7870932
Drug: Cocaine and
RxNorm normalized name: Cocaine and morphine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine and ethanol administration
Trial: 20721962
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of activated carbon nanoparticles
Trial: 20721962
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of methylene blue
Trial: 12660266
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg testosterone implant plus daily oral placebo
Trial: 12660266
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg testosterone plus oral Q 75 microg/day
Trial: 12660266
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg testosterone plus oral Q 75 microg/day
Trial: 11766652
Drug: Alternative therapies
RxNorm normalized name: HERBS/ALTERNATIVE THERAPIES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative therapies such as conservative treatment and plating
Trial: 7877826
Drug: 131I-HIPDM injection
RxNorm normalized name: iobenguane (131I)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 131I-HIPDM injection
Trial: 19113926
Drug: Daily teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily teriparatide for 15 months
Trial: 9279891
Drug: Radiolabelled pessary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiolabelled pessary formulation
Trial: 9279891
Drug: Replens (polycarbophil)
RxNorm normalized name: Aspergillus repens
DrugBank: Aspergillus repens (DB10449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replens (polycarbophil) gel
Trial: 23702236
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CPAP and speech therapy
Trial: 23702236
Drug: Placebo (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sham speech therapy)
Trial: 16420253
Drug: Trizivir (TZV)
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Trizivir (TZV) twice daily (n = 85)
Trial: 16420253
Drug: Combivir/nelfinavir (COM/NFV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combivir/nelfinavir (COM/NFV) 1250 mg twice daily (n = 88)
Trial: 16420253
Drug: Stavudine/lamivudine/nelfinavir (d4T/3TC/NFV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine/lamivudine/nelfinavir (d4T/3TC/NFV) 40 mg+150 mg+1250 mg twice daily (n = 81)